Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Talkspace operates a digital behavioral health platform connecting patients with licensed therapists via text, video, and audio messaging across all 50 US states. The company monetizes through B2B2C contracts with health plans, employers, and government payers (including Medicare Advantage and Medicaid), plus direct-to-consumer subscriptions. Recent inflection to profitability driven by improved unit economics as platform scales and CAC efficiency improves.
Talkspace operates an asset-light marketplace model, taking 30-40% of session fees while therapists retain 60-70%. Revenue per member depends on utilization rates (sessions per enrolled member) and contract type. Enterprise contracts provide predictable PMPM (per-member-per-month) fees regardless of utilization, creating high-margin recurring revenue once customer acquisition costs are recovered. Competitive advantages include network density (thousands of licensed providers across all states), proprietary matching algorithms, and integrated platform reducing therapist administrative burden. Gross margins of 46% reflect platform economics; path to sustained profitability requires scaling fixed technology/G&A costs across growing member base.
Enterprise contract wins and renewals - large health plan or employer deals materially impact forward revenue visibility
Member growth metrics - total members, paying members, and enterprise vs DTC mix drive revenue trajectory
Utilization rates and revenue per member - session frequency determines monetization of enrolled base
Path to sustained profitability - quarterly EBITDA progression and operating leverage demonstration
Competitive positioning vs BetterHelp, Lyra Health, Spring Health in enterprise channel
Regulatory developments around telehealth reimbursement and mental health parity enforcement
Regulatory uncertainty around telehealth reimbursement - temporary COVID-era flexibilities could expire, though bipartisan support for mental health access suggests permanence
Clinical efficacy scrutiny - digital-first therapy faces ongoing validation requirements vs traditional in-person care; outcomes data critical for enterprise renewals
Therapist supply constraints - licensed provider shortages could limit growth or increase costs; platform must maintain competitive economics for therapists vs private practice
Intense competition from BetterHelp (Teladoc), Lyra Health, Spring Health in enterprise channel - differentiation increasingly difficult as platforms commoditize
Health plan vertical integration - major insurers building internal telehealth capabilities could disintermediate third-party platforms
Traditional therapy practices adopting hybrid models - established providers adding digital tools reduces Talkspace's convenience advantage
Path to sustained profitability unproven - while recently profitable on net income basis, operating cash flow near zero and 1% FCF yield indicates fragile unit economics
Customer concentration risk - loss of large enterprise contract could materially impact revenue given B2B2C dominance
Equity dilution risk - if profitability trajectory falters, company may need additional capital raising given minimal cash generation
moderate - Mental health demand exhibits counter-cyclical characteristics (economic stress increases anxiety/depression), but ability to pay is pro-cyclical. Enterprise channel provides buffer as employers maintain benefits during downturns to retain talent. DTC segment more exposed to discretionary spending cuts. Overall, behavioral health is increasingly viewed as essential healthcare, reducing cyclicality vs traditional consumer discretionary.
Rising rates create valuation headwind for unprofitable growth companies, compressing forward revenue multiples. Operationally, Talkspace has zero debt and $40M+ cash, eliminating financing cost sensitivity. However, higher rates increase discount rates applied to future cash flows, pressuring 3.1x P/S multiple. Path to sustained profitability reduces rate sensitivity over time as company transitions from growth story to profitable compounder narrative.
Minimal direct exposure. Zero debt on balance sheet and 5.91x current ratio indicate strong liquidity. Enterprise customers (health plans, large employers) have low default risk. DTC subscriptions are prepaid monthly, eliminating receivables risk. Indirect exposure through employer budget constraints during credit tightening, but behavioral health benefits typically protected given rising mental health crisis and regulatory mandates.
growth - Recent 53% six-month return and 25% revenue growth attract momentum investors betting on digital health adoption and operating leverage inflection. Small $700M market cap appeals to small-cap growth funds. Recent profitability inflection (106% net income growth) draws investors seeking early-stage turnaround stories. High volatility and execution risk deter value investors despite 3.1x P/S appearing reasonable vs SaaS comps.
high - Small-cap healthcare technology stock with limited analyst coverage and institutional ownership. 27% three-month return followed by modest one-year return demonstrates episodic volatility around earnings and contract announcements. Illiquid float amplifies price swings. Beta likely 1.5-2.0x given growth profile and sector.
